Differential diagnosis and management issues of idiopathic angiooedema and their resolution

1. Bravi L, Dejana E, Lampugnani MG. VE-cadherin at a glance. Cell Tissue Res. 2014;355(3):515-22.10.1007/s00441-014-1843-7Search in Google Scholar

2. Orsenigo F, Giampietro C, Ferrari A et al. Phosphorylation of VEcadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun. 2012;3:1208.10.1038/ncomms2199Search in Google Scholar

3. Cicardi M, Aberer W, Banerji A et al. Classification, diagnosis, and approach to treatment for angiooedema: consensus report from the Hereditary Angiooedema International Working Group. Allergy. 2014;69(5):602-16.10.1111/all.12380Search in Google Scholar

4. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angiooedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213-7.10.1016/S0140-6736(00)02483-1Search in Google Scholar

5. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angiooedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286-9.10.1016/j.bbrc.2006.03.092Search in Google Scholar

6. Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angiooedema type III. Am J Hum Genet. 2006;79(6):1098-104.10.1086/509899Search in Google Scholar

7. Bork K, Kleist R, Hardt J, Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angiooedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis. 2009;20(5):325-32.10.1097/MBC.0b013e32832811f8Search in Google Scholar

8. Mansi M, Zanichelli A, Coerezza A et al. Presentation, diagnosis and treatment of angiooedema without wheals: retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015;277(5):585-93.10.1111/joim.12304Search in Google Scholar

9. Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angiooedema. Am J Med. 1999;106(6):650-4.10.1016/S0002-9343(99)00123-0Search in Google Scholar

10. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykininreceptor antagonist, in hereditary angiooedema. N Engl J Med. 2010;363(6):532-41.10.1056/NEJMoa0906393Search in Google Scholar

11. Kaplan AP. Angiooedema. World Allergy Organ J. 2008;1(6):103-13.10.1097/WOX.0b013e31817aecbeSearch in Google Scholar

12. Zuberbier T. A Summary of the New International EAACI/ GA2LEN/EDF/WAO Guidelines in Urticaria. World Allergy Organ J. 2012;5 Suppl 1:S1-5.10.1097/1939-4551-5-S1-S1Search in Google Scholar

13. Zingale LC, Beltrami L, Zanichelli A et al. Angiooedema without urticaria: a large clinical survey. CMAJ. 2006;175(9):1065-70.10.1503/cmaj.060535Search in Google Scholar

14. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angiooedema. N Engl J Med. 2002;347(8):621-2.10.1056/NEJM200208223470820Search in Google Scholar

15. Bygum AM, Aygoren-Pursun EM, Caballero TMP et al. The hereditary angiooedema burden of illness study in Europe (HAEBOIS- Europe): background and methodology. BMC Dermatol. 2012;12:4.10.1186/1471-5945-12-4Search in Google Scholar

16. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and longterm management of hereditary angiooedema. Ann Allergy Asthma Immunol. 2010;104(4):314-20.10.1016/j.anai.2010.01.024Search in Google Scholar

17. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angiooedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407-14.10.2500/aap.2010.31.3394Search in Google Scholar

18. Lin RY, Shah SN. Increasing hospitalizations due to angiooedema in the United States. Ann Allergy Asthma Immunol. 2008;101(2):185-92.10.1016/S1081-1206(10)60208-6Search in Google Scholar

19. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angiooedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011;66(2):192-6.10.1111/j.1398-9995.2010.02433.xSearch in Google Scholar

20. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angiooedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692-7.10.1016/j.jaci.2012.05.055Search in Google Scholar

21. Marcos C, Lopez Lera A, Varela S, Linares T, Alvarez-Eire MG, Lopez-Trascasa M. Clinical, biochemical, and genetic characterization of type III hereditary angiooedema in 13 Northwest Spanish families. Ann Allergy Asthma Immunol. 2012;109(3):195-200.10.1016/j.anai.2012.05.022Search in Google Scholar

22. Vitrat-Hincky V, Gompel A, Dumestre-Perard C et al. Type III hereditary angio-ooedema: clinical and biological features in a French cohort. Allergy. 2010;65(10):1331-6.10.1111/j.1398-9995.2010.02368.xSearch in Google Scholar

23. Bork K. Hereditary angiooedema with normal C1 inhibitor. Immunol Allergy Clin North Am. 2013;33(4):457-70.10.1016/j.iac.2013.07.002Search in Google Scholar